| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 32 | 2023 | 1429 | 4.870 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 20 | 2023 | 1664 | 3.270 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 11 | 2020 | 301 | 2.920 |
Why?
|
| Radiotherapy, Intensity-Modulated | 14 | 2020 | 2104 | 2.620 |
Why?
|
| Radiation Oncology | 9 | 2023 | 529 | 2.130 |
Why?
|
| Lymphoma | 11 | 2021 | 1467 | 1.760 |
Why?
|
| Mediastinal Neoplasms | 7 | 2021 | 423 | 1.750 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2021 | 1039 | 1.570 |
Why?
|
| Radiotherapy | 12 | 2020 | 1824 | 1.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 40 | 2023 | 15862 | 1.530 |
Why?
|
| Pregnancy Complications, Neoplastic | 3 | 2017 | 222 | 1.530 |
Why?
|
| Positron Emission Tomography Computed Tomography | 12 | 2021 | 833 | 1.380 |
Why?
|
| Doxorubicin | 18 | 2021 | 3005 | 1.300 |
Why?
|
| Organs at Risk | 4 | 2020 | 514 | 1.170 |
Why?
|
| Radiotherapy, Image-Guided | 3 | 2019 | 304 | 1.070 |
Why?
|
| Stomach Neoplasms | 6 | 2020 | 2278 | 1.070 |
Why?
|
| Central Nervous System Neoplasms | 8 | 2021 | 502 | 1.070 |
Why?
|
| Salvage Therapy | 14 | 2021 | 2054 | 1.060 |
Why?
|
| Radiotherapy Dosage | 23 | 2020 | 3842 | 1.010 |
Why?
|
| Lymphoma, Follicular | 5 | 2020 | 587 | 0.960 |
Why?
|
| Cyclophosphamide | 10 | 2022 | 3001 | 0.890 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2021 | 2370 | 0.880 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2023 | 10035 | 0.880 |
Why?
|
| Vincristine | 8 | 2019 | 1511 | 0.860 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2021 | 32 | 0.820 |
Why?
|
| Leukemia | 4 | 2018 | 1635 | 0.810 |
Why?
|
| Positron-Emission Tomography | 10 | 2022 | 2173 | 0.810 |
Why?
|
| Bleomycin | 10 | 2023 | 467 | 0.790 |
Why?
|
| Neoplasm Staging | 27 | 2020 | 13658 | 0.790 |
Why?
|
| Combined Modality Therapy | 24 | 2021 | 8865 | 0.790 |
Why?
|
| Prednisone | 6 | 2019 | 984 | 0.780 |
Why?
|
| Humans | 132 | 2024 | 261506 | 0.760 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 23 | 0.760 |
Why?
|
| Internationality | 2 | 2020 | 208 | 0.760 |
Why?
|
| Vinblastine | 10 | 2020 | 453 | 0.750 |
Why?
|
| Racism | 1 | 2021 | 50 | 0.730 |
Why?
|
| Adult | 67 | 2023 | 77950 | 0.710 |
Why?
|
| Radiation Injuries | 9 | 2020 | 1411 | 0.700 |
Why?
|
| Radiation Exposure | 1 | 2020 | 73 | 0.690 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2022 | 191 | 0.690 |
Why?
|
| Dacarbazine | 10 | 2020 | 485 | 0.690 |
Why?
|
| Chemoradiotherapy | 8 | 2021 | 1946 | 0.690 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2019 | 713 | 0.690 |
Why?
|
| Spinal Cord Diseases | 2 | 2017 | 90 | 0.680 |
Why?
|
| Lymphoma, B-Cell | 4 | 2021 | 895 | 0.670 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2023 | 6550 | 0.630 |
Why?
|
| Heart | 6 | 2020 | 1223 | 0.630 |
Why?
|
| Aged | 61 | 2023 | 70117 | 0.630 |
Why?
|
| Middle Aged | 67 | 2022 | 86204 | 0.620 |
Why?
|
| Gastric Mucosa | 2 | 2019 | 613 | 0.620 |
Why?
|
| Lymphocytes | 3 | 2020 | 1234 | 0.620 |
Why?
|
| Methotrexate | 4 | 2017 | 999 | 0.610 |
Why?
|
| Retrospective Studies | 44 | 2023 | 37905 | 0.590 |
Why?
|
| Eye Neoplasms | 2 | 2017 | 247 | 0.570 |
Why?
|
| Radiation Pneumonitis | 2 | 2016 | 301 | 0.570 |
Why?
|
| Male | 69 | 2021 | 123000 | 0.570 |
Why?
|
| Students, Medical | 1 | 2022 | 399 | 0.560 |
Why?
|
| Young Adult | 33 | 2021 | 21445 | 0.560 |
Why?
|
| Hypothyroidism | 1 | 2018 | 204 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 810 | 0.550 |
Why?
|
| Female | 72 | 2022 | 141928 | 0.550 |
Why?
|
| Radiation Dosage | 1 | 2020 | 1014 | 0.540 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.530 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 1763 | 0.520 |
Why?
|
| Abortion, Spontaneous | 1 | 2016 | 112 | 0.520 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 598 | 0.520 |
Why?
|
| Receptor, Notch1 | 4 | 2009 | 218 | 0.500 |
Why?
|
| Survival Rate | 16 | 2021 | 12221 | 0.490 |
Why?
|
| Peritoneal Neoplasms | 2 | 2019 | 821 | 0.480 |
Why?
|
| Testicular Neoplasms | 2 | 2018 | 529 | 0.480 |
Why?
|
| Internship and Residency | 5 | 2023 | 1375 | 0.470 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 260 | 0.460 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2020 | 7551 | 0.460 |
Why?
|
| Treatment Outcome | 29 | 2021 | 32848 | 0.460 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 1299 | 0.460 |
Why?
|
| Etoposide | 5 | 2018 | 870 | 0.450 |
Why?
|
| Disease-Free Survival | 14 | 2021 | 10001 | 0.450 |
Why?
|
| Emollients | 1 | 2011 | 12 | 0.420 |
Why?
|
| Petrolatum | 1 | 2011 | 11 | 0.420 |
Why?
|
| Recurrence | 12 | 2021 | 4758 | 0.420 |
Why?
|
| Communication | 1 | 2018 | 876 | 0.420 |
Why?
|
| Aged, 80 and over | 29 | 2022 | 29902 | 0.400 |
Why?
|
| Radiodermatitis | 1 | 2011 | 75 | 0.400 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2403 | 0.400 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 128 | 0.390 |
Why?
|
| Melanocytes | 2 | 2009 | 219 | 0.390 |
Why?
|
| Rituximab | 8 | 2023 | 1528 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 5178 | 0.390 |
Why?
|
| Fluorodeoxyglucose F18 | 6 | 2022 | 1226 | 0.390 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2011 | 86 | 0.380 |
Why?
|
| Follow-Up Studies | 21 | 2022 | 14889 | 0.370 |
Why?
|
| Hyaluronic Acid | 1 | 2011 | 168 | 0.370 |
Why?
|
| Multiple Myeloma | 5 | 2022 | 2138 | 0.370 |
Why?
|
| Lung | 3 | 2016 | 3151 | 0.360 |
Why?
|
| Abdominal Neoplasms | 1 | 2011 | 231 | 0.350 |
Why?
|
| Prognosis | 17 | 2022 | 21713 | 0.350 |
Why?
|
| Plasmacytoma | 2 | 2021 | 111 | 0.340 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.340 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2020 | 726 | 0.330 |
Why?
|
| Transplantation, Autologous | 8 | 2023 | 1914 | 0.330 |
Why?
|
| Adolescent | 26 | 2021 | 31252 | 0.330 |
Why?
|
| Biopsy | 8 | 2022 | 3443 | 0.320 |
Why?
|
| Tumor Burden | 5 | 2019 | 1987 | 0.320 |
Why?
|
| Orbital Neoplasms | 3 | 2020 | 224 | 0.320 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2020 | 6207 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2019 | 864 | 0.300 |
Why?
|
| Breath Holding | 2 | 2017 | 44 | 0.300 |
Why?
|
| Radiopharmaceuticals | 3 | 2017 | 1301 | 0.290 |
Why?
|
| Thymus Neoplasms | 2 | 2023 | 400 | 0.280 |
Why?
|
| Intraocular Lymphoma | 2 | 2016 | 15 | 0.280 |
Why?
|
| Survival Analysis | 9 | 2022 | 9180 | 0.270 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 4988 | 0.260 |
Why?
|
| Dexamethasone | 3 | 2021 | 1450 | 0.250 |
Why?
|
| Disease Management | 4 | 2019 | 1052 | 0.250 |
Why?
|
| Receptors, Notch | 1 | 2007 | 383 | 0.250 |
Why?
|
| Craniospinal Irradiation | 2 | 2017 | 128 | 0.250 |
Why?
|
| Cancer Survivors | 2 | 2021 | 650 | 0.240 |
Why?
|
| Antigens, CD19 | 3 | 2022 | 577 | 0.230 |
Why?
|
| Disease Progression | 13 | 2021 | 6682 | 0.230 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 15694 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 4367 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2021 | 125 | 0.220 |
Why?
|
| Risk Assessment | 5 | 2018 | 6869 | 0.210 |
Why?
|
| Heterocyclic Compounds | 1 | 2022 | 119 | 0.210 |
Why?
|
| Skin | 1 | 2007 | 1259 | 0.210 |
Why?
|
| Radiometry | 4 | 2021 | 980 | 0.200 |
Why?
|
| Paraproteins | 1 | 2021 | 39 | 0.190 |
Why?
|
| Women's Health | 1 | 2022 | 205 | 0.190 |
Why?
|
| Stem Cells | 1 | 2007 | 1213 | 0.190 |
Why?
|
| Biological Products | 2 | 2020 | 274 | 0.180 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2020 | 49 | 0.180 |
Why?
|
| Piperidines | 2 | 2022 | 1035 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2023 | 1335 | 0.180 |
Why?
|
| Pregnancy | 3 | 2017 | 7573 | 0.180 |
Why?
|
| Nose | 1 | 2021 | 192 | 0.180 |
Why?
|
| Radium | 1 | 2020 | 93 | 0.180 |
Why?
|
| Dura Mater | 1 | 2019 | 73 | 0.180 |
Why?
|
| Injections, Spinal | 2 | 2017 | 257 | 0.170 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2020 | 113 | 0.170 |
Why?
|
| Salivary Glands | 1 | 2019 | 130 | 0.170 |
Why?
|
| CD4-CD8 Ratio | 1 | 2018 | 58 | 0.170 |
Why?
|
| Neoplasms | 6 | 2021 | 15193 | 0.170 |
Why?
|
| Coronary Restenosis | 1 | 2019 | 63 | 0.170 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 550 | 0.170 |
Why?
|
| Mesentery | 1 | 2019 | 72 | 0.170 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 2638 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2019 | 2231 | 0.160 |
Why?
|
| Analysis of Variance | 4 | 2016 | 2307 | 0.160 |
Why?
|
| Treatment Failure | 4 | 2018 | 1391 | 0.160 |
Why?
|
| Medicare | 1 | 2023 | 860 | 0.160 |
Why?
|
| Simulation Training | 1 | 2020 | 149 | 0.160 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 987 | 0.160 |
Why?
|
| Brain Neoplasms | 4 | 2018 | 4849 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 544 | 0.150 |
Why?
|
| Electrons | 1 | 2018 | 168 | 0.150 |
Why?
|
| Subacute Combined Degeneration | 1 | 2017 | 16 | 0.150 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2017 | 15 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2018 | 9244 | 0.150 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2017 | 80 | 0.150 |
Why?
|
| Heart Diseases | 2 | 2021 | 732 | 0.150 |
Why?
|
| Cytarabine | 4 | 2018 | 1973 | 0.150 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2019 | 314 | 0.150 |
Why?
|
| Breast Implants | 1 | 2022 | 391 | 0.140 |
Why?
|
| Platelet Count | 1 | 2017 | 490 | 0.140 |
Why?
|
| United States | 6 | 2024 | 15433 | 0.140 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 229 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2024 | 806 | 0.140 |
Why?
|
| Organ Specificity | 1 | 2018 | 699 | 0.140 |
Why?
|
| Homocysteine | 1 | 2017 | 138 | 0.140 |
Why?
|
| Leukocyte Count | 1 | 2017 | 684 | 0.140 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 565 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2992 | 0.140 |
Why?
|
| Cranial Irradiation | 2 | 2015 | 315 | 0.140 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2016 | 52 | 0.140 |
Why?
|
| Inhalation | 2 | 2017 | 42 | 0.140 |
Why?
|
| Conjunctival Neoplasms | 1 | 2017 | 120 | 0.140 |
Why?
|
| Hydroxamic Acids | 2 | 2016 | 442 | 0.140 |
Why?
|
| Skin Neoplasms | 4 | 2020 | 4654 | 0.140 |
Why?
|
| Orbit | 1 | 2017 | 205 | 0.130 |
Why?
|
| Hypopituitarism | 1 | 2015 | 33 | 0.130 |
Why?
|
| Abortion, Induced | 1 | 2016 | 91 | 0.130 |
Why?
|
| Uncertainty | 1 | 2017 | 320 | 0.130 |
Why?
|
| Melphalan | 4 | 2023 | 834 | 0.130 |
Why?
|
| Mycosis Fungoides | 1 | 2018 | 320 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2018 | 279 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2016 | 1546 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2019 | 739 | 0.130 |
Why?
|
| Stem Cell Transplantation | 5 | 2022 | 1360 | 0.130 |
Why?
|
| Organ Sparing Treatments | 1 | 2017 | 277 | 0.130 |
Why?
|
| Postpartum Period | 1 | 2016 | 259 | 0.130 |
Why?
|
| Spinal Cord | 2 | 2015 | 690 | 0.130 |
Why?
|
| Eye Diseases | 1 | 2016 | 132 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 1493 | 0.120 |
Why?
|
| Folic Acid | 1 | 2017 | 349 | 0.120 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 430 | 0.120 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 501 | 0.120 |
Why?
|
| Mammaplasty | 1 | 2022 | 780 | 0.120 |
Why?
|
| Cranial Nerve Diseases | 1 | 2014 | 73 | 0.120 |
Why?
|
| Time Factors | 8 | 2022 | 12926 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 361 | 0.120 |
Why?
|
| Brachytherapy | 1 | 2020 | 977 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 441 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 643 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 524 | 0.120 |
Why?
|
| Biomarkers | 4 | 2019 | 5047 | 0.110 |
Why?
|
| Coronary Angiography | 2 | 2019 | 598 | 0.110 |
Why?
|
| Neutrophils | 1 | 2017 | 835 | 0.110 |
Why?
|
| Radiosurgery | 2 | 2012 | 1330 | 0.110 |
Why?
|
| Coronary Artery Disease | 2 | 2019 | 1011 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 629 | 0.110 |
Why?
|
| Equipment Failure | 1 | 2013 | 191 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2007 | 11965 | 0.110 |
Why?
|
| Blood Platelets | 1 | 2017 | 731 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 726 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4892 | 0.110 |
Why?
|
| Helicobacter pylori | 2 | 2020 | 1295 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1559 | 0.110 |
Why?
|
| Breast | 3 | 2018 | 1344 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2015 | 246 | 0.110 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 361 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3981 | 0.100 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 85 | 0.100 |
Why?
|
| Pons | 1 | 2012 | 51 | 0.100 |
Why?
|
| Duodenum | 1 | 2012 | 149 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 7702 | 0.100 |
Why?
|
| Mediastinum | 3 | 2019 | 268 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1959 | 0.100 |
Why?
|
| Quality of Life | 3 | 2021 | 4532 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2011 | 257 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4298 | 0.100 |
Why?
|
| Melanoma | 5 | 2012 | 5317 | 0.100 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2012 | 226 | 0.100 |
Why?
|
| Pacemaker, Artificial | 1 | 2013 | 213 | 0.100 |
Why?
|
| Brain Stem Neoplasms | 1 | 2012 | 108 | 0.100 |
Why?
|
| Fertility Agents, Female | 1 | 2010 | 14 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 4744 | 0.100 |
Why?
|
| Single-Blind Method | 1 | 2011 | 409 | 0.100 |
Why?
|
| Defibrillators, Implantable | 1 | 2013 | 221 | 0.090 |
Why?
|
| Interferons | 1 | 2011 | 291 | 0.090 |
Why?
|
| Organ Size | 1 | 2011 | 690 | 0.090 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 189 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1870 | 0.090 |
Why?
|
| Foreskin | 1 | 2009 | 8 | 0.090 |
Why?
|
| Child | 8 | 2021 | 29154 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 212 | 0.090 |
Why?
|
| CD146 Antigen | 1 | 2009 | 57 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2016 | 1863 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 291 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2017 | 2358 | 0.090 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2010 | 101 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 363 | 0.090 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2011 | 137 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 1162 | 0.090 |
Why?
|
| Camptothecin | 1 | 2011 | 517 | 0.080 |
Why?
|
| Diet | 1 | 2017 | 1440 | 0.080 |
Why?
|
| Neoplasm Grading | 3 | 2019 | 1742 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2195 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2017 | 929 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 1399 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 402 | 0.080 |
Why?
|
| Central Nervous System | 2 | 2021 | 436 | 0.080 |
Why?
|
| Busulfan | 3 | 2018 | 764 | 0.080 |
Why?
|
| Kidney | 1 | 2017 | 2146 | 0.080 |
Why?
|
| Bevacizumab | 1 | 2011 | 938 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2020 | 3518 | 0.080 |
Why?
|
| Movement | 1 | 2011 | 556 | 0.080 |
Why?
|
| Remission Induction | 3 | 2018 | 3569 | 0.070 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 510 | 0.070 |
Why?
|
| Deoxycytidine | 3 | 2018 | 1353 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 846 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2022 | 5542 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 2238 | 0.070 |
Why?
|
| Coronary Vessels | 1 | 2011 | 665 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2011 | 2292 | 0.070 |
Why?
|
| Mastectomy, Segmental | 1 | 2011 | 1026 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2009 | 2450 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 5767 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 3251 | 0.070 |
Why?
|
| Cell Division | 1 | 2009 | 2489 | 0.060 |
Why?
|
| Glycolysis | 2 | 2019 | 519 | 0.060 |
Why?
|
| Phantoms, Imaging | 2 | 2020 | 1271 | 0.060 |
Why?
|
| Cisplatin | 1 | 2011 | 2432 | 0.060 |
Why?
|
| Risk | 2 | 2020 | 1972 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2006 | 371 | 0.060 |
Why?
|
| Proton Therapy | 1 | 2013 | 1577 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2020 | 16273 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2015 | 2390 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 5673 | 0.060 |
Why?
|
| Cadherins | 1 | 2006 | 660 | 0.050 |
Why?
|
| Supreme Court Decisions | 1 | 2022 | 12 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 3639 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2006 | 1678 | 0.050 |
Why?
|
| Homeostasis | 1 | 2007 | 950 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2023 | 76 | 0.050 |
Why?
|
| Accreditation | 1 | 2023 | 126 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2576 | 0.050 |
Why?
|
| Retreatment | 2 | 2014 | 452 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2015 | 3341 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 848 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 232 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2006 | 2054 | 0.050 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 1656 | 0.050 |
Why?
|
| beta Catenin | 1 | 2005 | 688 | 0.050 |
Why?
|
| British Columbia | 1 | 2021 | 24 | 0.050 |
Why?
|
| Neurons | 1 | 2012 | 2287 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2022 | 266 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 14289 | 0.050 |
Why?
|
| Linguistics | 1 | 2020 | 25 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2022 | 593 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2006 | 1385 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 151 | 0.050 |
Why?
|
| Safety | 1 | 2022 | 465 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2022 | 12873 | 0.050 |
Why?
|
| Sexism | 1 | 2020 | 51 | 0.050 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 4821 | 0.050 |
Why?
|
| Palliative Care | 1 | 2012 | 2037 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 1833 | 0.050 |
Why?
|
| Bias | 1 | 2020 | 205 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2006 | 1048 | 0.040 |
Why?
|
| Prevalence | 2 | 2019 | 3260 | 0.040 |
Why?
|
| Personnel Selection | 1 | 2020 | 87 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 3472 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 749 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 406 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 5687 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2020 | 298 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2013 | 4557 | 0.040 |
Why?
|
| Carmustine | 1 | 2018 | 214 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2006 | 3343 | 0.040 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 131 | 0.040 |
Why?
|
| Phenotype | 1 | 2009 | 6295 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2020 | 388 | 0.040 |
Why?
|
| Autografts | 1 | 2018 | 165 | 0.040 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 387 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 700 | 0.040 |
Why?
|
| Adenine | 1 | 2020 | 631 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 671 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 1819 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 978 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 292 | 0.040 |
Why?
|
| Mutation | 1 | 2016 | 15179 | 0.040 |
Why?
|
| Pentostatin | 1 | 2016 | 119 | 0.030 |
Why?
|
| Procarbazine | 1 | 2015 | 69 | 0.030 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2017 | 202 | 0.030 |
Why?
|
| Photopheresis | 1 | 2016 | 79 | 0.030 |
Why?
|
| Endothelium | 1 | 2016 | 158 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2012 | 1764 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1146 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 193 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2015 | 3890 | 0.030 |
Why?
|
| Survivors | 1 | 2021 | 1031 | 0.030 |
Why?
|
| Myelin Basic Protein | 1 | 2015 | 85 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 5061 | 0.030 |
Why?
|
| Facial Nerve Diseases | 1 | 2014 | 21 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2020 | 1529 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 671 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 756 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 860 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2016 | 335 | 0.030 |
Why?
|
| Axilla | 1 | 2017 | 902 | 0.030 |
Why?
|
| Animals | 5 | 2016 | 59536 | 0.030 |
Why?
|
| Protons | 1 | 2017 | 473 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 329 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 829 | 0.030 |
Why?
|
| Leukemia, B-Cell | 1 | 2015 | 117 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 166 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 918 | 0.030 |
Why?
|
| Risk Factors | 3 | 2017 | 17523 | 0.030 |
Why?
|
| Contraindications | 1 | 2013 | 150 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 1033 | 0.030 |
Why?
|
| Photons | 1 | 2017 | 507 | 0.030 |
Why?
|
| Pericardium | 1 | 2015 | 157 | 0.030 |
Why?
|
| Optic Nerve Diseases | 1 | 2014 | 103 | 0.030 |
Why?
|
| Neutrons | 1 | 2013 | 117 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 2015 | 196 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 461 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2013 | 219 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 358 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 329 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 6311 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 7789 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 2796 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 1270 | 0.030 |
Why?
|
| N-Methylaspartate | 1 | 2012 | 50 | 0.030 |
Why?
|
| Memantine | 1 | 2012 | 46 | 0.030 |
Why?
|
| Receptors, GABA-A | 1 | 2012 | 79 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 752 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 1350 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2012 | 182 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2006 | 1869 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2020 | 1471 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 1442 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 1586 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2012 | 471 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 2020 | 1216 | 0.020 |
Why?
|
| Biological Transport | 1 | 2012 | 597 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2012 | 176 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 2013 | 337 | 0.020 |
Why?
|
| Medical Records | 1 | 2012 | 415 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 2843 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 1375 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1149 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.020 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2012 | 259 | 0.020 |
Why?
|
| Trans-Activators | 2 | 2006 | 1555 | 0.020 |
Why?
|
| Walking | 1 | 2012 | 277 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 3719 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 443 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1245 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4320 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2019 | 2967 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 2063 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2011 | 873 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 6009 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2011 | 884 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 342 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2005 | 149 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 3976 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2006 | 222 | 0.020 |
Why?
|
| COS Cells | 1 | 2005 | 377 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13310 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 7548 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3022 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2012 | 4804 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2005 | 269 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 639 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2006 | 1008 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 6086 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 2527 | 0.010 |
Why?
|
| Cell Proliferation | 2 | 2006 | 7226 | 0.010 |
Why?
|
| Triglycerides | 1 | 2005 | 603 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 1519 | 0.010 |
Why?
|
| Transcription Factors | 2 | 2006 | 5270 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 891 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5112 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2006 | 14551 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 4975 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 5114 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 6915 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2012 | 11538 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 5319 | 0.010 |
Why?
|
| Mice | 2 | 2006 | 34495 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 4053 | 0.010 |
Why?
|